公开(公告)号：US20240228464A9

公开(公告)日：2024-07-11

申请号：US18383949

申请日：2023-10-26

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Xuechao Xing ,  Yong He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:




which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US11976084B2

公开(公告)日：2024-05-07

申请号：US17531844

申请日：2021-11-22

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jun Ma ,  Yong He ,  Xuechao Xing ,  Hui Cao ,  Xuri Gao ,  Xiaowen Peng ,  Joseph D. Panarese ,  Yat Sun Or

IPC: C07D519/00

CPC classification number: C07D519/00

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220162216A1

公开(公告)日：2022-05-26

申请号：US17479244

申请日：2021-09-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Yong He ,  Xuri Gao ,  Jun Ma ,  Xuechao Xing ,  Hui Cao ,  Joseph D. Panarese ,  Yat Sun Or

IPC: C07D487/10

Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11034684B2

公开(公告)日：2021-06-15

申请号：US16569819

申请日：2019-09-13

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jun Ma ,  Guoqiang Wang ,  Bin Wang ,  Xuechao Xing ,  Ruichao Shen ,  Jing He ,  Yat Sun Or

IPC: C07D417/14 ,  C07D413/14 ,  C07D261/08 ,  C07D413/12

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US11008304B2

公开(公告)日：2021-05-18

申请号：US16400529

申请日：2019-05-01

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Xuechao Xing ,  Yong He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US10683289B2

公开(公告)日：2020-06-16

申请号：US16400498

申请日：2019-05-01

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yat Sun Or

IPC: C07D417/14 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/4439

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis disease (NASH).

公开(公告)号：US20200157095A1

公开(公告)日：2020-05-21

申请号：US16688429

申请日：2019-11-19

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Bin Wang ,  Yat Sun Or

IPC: C07D471/04 ,  C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US20200079764A1

公开(公告)日：2020-03-12

申请号：US16569819

申请日：2019-09-13

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jun Ma ,  Guoqiang Wang ,  Bin Wang ,  Xuechao Xing ,  Ruichao Shen ,  Jing He ,  Yat Sun Or

IPC: C07D413/14 ,  C07D413/12 ,  C07D261/08 ,  C07D417/14

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US20190248777A1

公开(公告)日：2019-08-15

申请号：US16272506

申请日：2019-02-11

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Ruichao Shen ,  Jun Ma ,  Guoqiang Wang ,  Xuechao Xing ,  Yat Sun Or

IPC: C07D417/04 ,  A61P1/16 ,  A61P13/12 ,  A61P9/10 ,  A61P3/04 ,  A61P3/10

Abstract: The present invention provides compounds of Formula (I): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US10253018B2

公开(公告)日：2019-04-09

申请号：US15988763

申请日：2018-05-24

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Brett Granger ,  Ruichao Shen ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D401/04 ,  C07D491/107 ,  C07D498/08

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).